Excess Prepregnancy Parental Adiposity Linked to Offspring MASLD
via HealthDayWEDNESDAY, March 4, 2026 -- Prepregnancy parental overweight or obesity is associated with increased odds of offspring metabolic dysfunction-associated steatotic liver disease (MASLD) in adulthood, according to a study published online Feb. 24 in Gut.
Stefani Tica, M.D., from Washington University School of Medicine in St. Louis, and colleagues examined prospective associations between prepregnancy biparental adiposity and offspring MASLD in adulthood (age 24 years) in a study of 1,933 offspring from the U.K. Avon Longitudinal Study of Parents and Children.
The researchers found that 10.4 percent of offspring had MASLD at age 24 years. Independent associations were seen for prepregnancy maternal and paternal obesity with increased odds of offspring MASLD. Each 1-kg/m2 increase in maternal and paternal body mass index (BMI) increased the odds of MASLD by 10 and 9 percent, respectively (odds ratios, 1.10 and 1.09). The odds of offspring MASLD were further increased with biparental overweight or obesity (odds ratio, 3.73) compared with parents with a normal BMI. Cumulative excess childhood BMI mediated 67 percent of this association, with a defined area under the curve for BMI z score >1 for ages 7 to 17 years.
"We found that not only maternal but also paternal obesity increased the risk of offspring MASLD. Although the mechanisms behind this association are complex, our study suggests a window where early intervention on excess adiposity may decrease the burden of MASLD among future generations," the authors write.
One author disclosed ties to Need and Bayer.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-03-05 01:43
Read more
- New Guideline Details Diagnosis, Treatment of Acute Pulmonary Embolism
- Moderna’s mRNA Flu Vaccine Back Under FDA Review
- FDA Approves Hernexeos, the First Targeted Therapy for Adults with HER2-Mutant Advanced NSCLC as an Initial Treatment Option
- Deciphera Pharmaceuticals Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory PCNSL
- Metabolic Dysfunction Is Main Driver of Chronic Kidney Disease Risk
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions